Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Ozelle Demonstrates AI-Powered Diagnostic Workflows at WHX Labs Dubai 2026

By LabMedica International staff writers
Posted on 11 Feb 2026

At WHX Labs Dubai 2026, Ozelle is exhibiting its advanced diagnostic workflow solution under the theme “AI × CBM: The Next Generation of Complete Blood Morphology. More...

” The system is designed to support decision-ready laboratory workflows by integrating high-resolution morphology imaging, AI-assisted analysis, and scenario-specific diagnostic panels.

Central to the on-site demonstrations is the Intelligent AI Workbench (Open Dx), a unified diagnostic workspace embedded within the analyzer. It converts raw laboratory results into structured, interactive insights, guiding clinicians through actionable information.

Key features include risk stratification, conversational AI report interpretation, critical alerts, and follow-up trend analysis. By integrating test ordering, result review, and AI-assisted interpretation into a single, intuitive workflow, the workbench supports confident, efficient decisions without adding operational burden or extensive training.

Live demonstrations at the exhibition highlight the system’s versatility across multiple clinical scenarios, including infection profiling with combined CBC, CRP, and SAA testing in a single fully automated run without manual reagent switching. The platform also supports everyday disease management through flexible, customizable panels for diabetes, cardiac, and thyroid monitoring, enabling repeatable, high-frequency testing without added workflow complexity. 

In addition, AI-powered morphology analysis for malaria risk screening detects red blood cell patterns associated with Plasmodium, delivering high-, medium-, and low-risk indications to support early screening and follow-up in endemic regions. Together, these scenario-ready capabilities show how Ozelle extends advanced morphology intelligence beyond routine CBC to address both everyday clinical care and high-risk public health needs.

At the foundation of Ozelle's system is AI-powered Complete Blood Morphology (CBM), which combines high-resolution imaging with real-time algorithmic analysis for deeper, actionable insights. Combined with a maintenance-free, easy-to-use device design, the system delivers long-term reliability, ideal for primary care clinics, chain laboratories, and decentralized testing sites.

Ozelle's technology is validated through 50,000+ global installations, generating 50 million+ cell images daily and over 100 billion real-world data points. Continuous algorithm refinement via an industry-exclusive quality control system ensures lab-grade performance that remains stable, scalable, and sustainable over time. 

Related Links:
Ozelle


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researchers identified blood-based genomic signatures characteristic of inflammatory breast cancer (photo courtesy of Shutterstock)

Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring

Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.